Blueprint Medicines Corp

Blueprint Medicines — Technical Presentation (October 2018)

16 slides from Blueprint Medicines's technical presentation, Oct 1, 2018

  1. Slide 1: BLU-782: A highly selective ALK2 inhibitor for FOP

    BLU-782 September 30th 2018 A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva Andrew Garner, Ph.D.

  2. Slide 2: Disclosures

    Disclosures I am an employee and stockholder of Blueprint Medicines Corporation (Blueprint Medicines) I will discuss the preclinical characterization of the investigational agent BLU-782, which is being developed by Blueprint Medicines

  3. Slide 3: Forward-looking statements

    Forward-looking statements 3 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project

  4. Slide 4: Acknowledgements

    Acknowledgements Alison Davis, Brian Hodous, Timothy LaBranche, Michael Sheets, Natasja Brooijmans, Joseph Kim, Brett Williams, Sean Kim, Lan Xu, John Vassiliadis, Paul Fleming, Mark Cronin, Julia Zhu, Ruduan Wang, Rachel Stewart, Chris Graul, Elliot Greenblatt, Keith Bouchard, Vivek Kadambi, Timoth

  5. Slide 5: Highly selective kinase medicines offer potential for improved potency and clinical success

    Highly selective kinase medicines offer potential for improved potency, less off-target activity and increased probability of clinical success SELECTIVE AVAPRITINIB NON-SELECTIVE SUNITINIB GENOMIC DRIVER SELECTED PATIENT POPULATION Blueprint Medicines is pioneering a new way of discovering and devel

  6. Slide 6: FOP is caused by mutant ALK2

    Fibrodysplasia ossificans progressiva (FOP) is caused by mutant ALK2 ALK2R206H mutations are found in 100% of FOP patients 85% – 97% are ALK2R206H ALK2R206H mice recapitulate all the key features of FOP Selective ALK2 inhibition targets the underlying cause of FOP TUMOR-LIKE SWELLINGS MALFORMED TOES

  7. Slide 7: ALK2 R206H causes FOP by changing the response to ligands

    ALK2R206H causes FOP by changing the response to ligands WILD TYPE ALK2R206H FOP 7 References: Hatsell et al., Sci Trans Med, 2015; Hino et al., PNAS, 2015 P P SMAD P SMAD BMP Activin Type I ALK2 Type II ACVR2A ACVR2B BMPR2 Muscle breakdown Heterotopic bone P P P P SMAD P SMAD P BMP Activin

  8. Slide 8: Selective ALK2 inhibition is important for chronic dosing

    Selective ALK2 inhibition is important for chronic dosing BMP Pathway ALKs: ALK1 / 3 / 6 ALK1 regulates blood vessels ALK3 regulates iron storage ALK6 regulates embryonic digit growth TGF β Pathway ALKs: ALK4 / 5 / 7 TGF β modulates the immune response; ALK4, 5, and 7 inhibition could cause systemic

  9. Slide 9: Blueprint's kinase library yielded multiple selective ALK2 start points

    Blueprint’s kinase library yielded multiple selective ALK2 start points ALK2 Spearman activity-based compound clustering >400 Kinases * * * “Anti-targets” * * * * * * * * * 9 Data on file. Blueprint Medicines Corporation 2018 Non-selective Selective Selective

  10. Slide 10: Structure-based drug design yielded BLU-782, a highly selective ALK2 inhibitor

    Structure-based drug design yielded BLU-782, a highly selective ALK2 inhibitor ALK2R206H ALK2 ALK1 ALK6 ALK3 Biochemical Cellular BLU-782 CRYSTAL STRUCTURE BLU-782 SELECTIVITY BLU-782 binding preserves a unique ALK2 water network 10 Kinome illustration reproduced courtesy of Cell Signaling Technolog

  11. Slide 11: BLU-782 potently inhibits ALK2 R206H irrespective of the activating ligand

    BLU-782 potently inhibits ALK2R206H irrespective of the activating ligand Canonical (BMP6) Non-canonical (activin) R206H WT Act A Act B R206H WT 11 Data on file. Blueprint Medicines Corporation 2018 P P P P SMAD SMAD P P BMP Activin BLU-782 0.1 1 10 100 1000 10000 0 10000 20000 30000 40000 50000 nM

  12. Slide 12: BLU-782 selectively targets the root cause of FOP

    BLU-782 selectively targets the root cause of FOP mCT (D17) T2-WEIGHTED MRI (D8) Control BLU-782 BLU-782 Control Pinch Pinch 12 BLU-782 prevents injury-induced heterotopic ossification (HO) in ALK2R206H mice Data on file. Blueprint Medicines Corporation 2018 No pinch No pinch Control BLU-782 0 10 20

  13. Slide 13: BLU-782 restores the normal tissue response to muscle injury in ALK2 R206H mice

    BLU-782 restores the normal tissue response to muscle injury in ALK2R206H mice CONTROL BLU-782 Day 7 Day 17 13 Data on file. Blueprint Medicines Corporation 2018

  14. Slide 14: BLU-782 inhibits surgery-induced HO in ALK2 R206H mice

    BLU-782 inhibits surgery-induced HO in ALK2R206H mice 14 BLU-782 prevents HO in a fibular osteotomy model in ALK2R206H mice BLU-782 does not impact fracture repair or surgical wound closure Data on file. Blueprint Medicines Corporation 2018 BLU-782 Control 0 12 29 50 Day 0 20 40 0 50 100 150 Days M

  15. Slide 15: BLU-782: an ALK2 kinase inhibitor specifically tailored for FOP

    BLU-782- an ALK2 kinase inhibitor specifically tailored for FOP BLU-782 IS HIGHLY SELECTIVE BLU-782 TARGETS THE ROOT CAUSE OF FOP 15 Plan to file an Investigational New Drug (IND) application for BLU-782 by end of 2018 Subject to approval of IND application by the FDA, plan to initiate Phase 1 healt

  16. Slide 16: Thank you

    Thank you

Blueprint Medicines — Technical Presentation (October 2018) on 6ix